Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19

INTRODUCTION: Tocilizumab, a humanized anti-interleukin-6 receptor (IL-6R) antibody, is recommended for the treatment of severe to critical coronavirus diseases 2019 (COVID-19). However, there were conflicting results on the efficacy of tocilizumab. Therefore, we hypothesized that the differences in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chan Mi, Kim, Minji, Kang, Chang Kyung, Choe, Pyoeng Gyun, Kim, Nam Joong, Bang, Hyeeun, Cho, Taeeun, Shin, Hyun Mu, Kim, Hang-Rae, Park, Wan Beom, Oh, Myoung-don
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110916/
https://www.ncbi.nlm.nih.gov/pubmed/37081872
http://dx.doi.org/10.3389/fimmu.2023.1110874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110916/
https://www.ncbi.nlm.nih.gov/pubmed/37081872
http://dx.doi.org/10.3389/fimmu.2023.1110874

Ejemplares similares